Brief: Microbot Medical To Enhance Focus On Its Core Business And Prioritize Preparations For Regulatory And First In Human Clinical Cases
18/05/2023 14:30
Microbot Medical Inc MBOT.O :
* MICROBOT MEDICAL TO ENHANCE FOCUS ON ITS CORE BUSINESS AND
PRIORITIZE PREPARATIONS FOR REGULATORY AND FIRST IN HUMAN
CLINICAL CASES
* MICROBOT MEDICAL INC - WILL ELIMINATE NON-CORE TECHNOLOGY
EXPENSES BY TERMINATING AGREEMENTS RELATING TO TIPCAT, VIROB AND
CARDIOSERT TECHNOLOGIES
* MICROBOT MEDICAL INC- IT EXECUTED SEVERAL COST REDUCTION
INITIATIVES TO REDUCE EXPENSES THAT ARE NOT DIRECTLY SUPPORTING
COMPANY'S CORE TECHNOLOGY
* MICROBOT MEDICAL INC- REDUCTION IN POSITIONS NOT DIRECTLY
SUPPORTING CORE LIBERTY TECHNOLOGY
* MICROBOT MEDICAL INC- EXECUTED COMPENSATION REDUCTIONS OR
RESTRUCTURINGS FOR ITS LEADERSHIP TEAM AND CERTAIN ADVISORS
Source text for Eikon: ID:nGNXcgZkKS
Further company coverage: MBOT.O
Recent news on Microbot Medical
See all newsBrief: Microbot Medical® Enters Into An Agreement To Expand Access For America’S Veteran And Military Patient Populations
Microbot Medical rises as U.S. federal supply deal expands reach of robotic surgical device
Brief: Microbot Medical Recorded Revenue During Its Quarter Ended March 31, Benefiting From Limited Market Release Of Liberty System
Brief: Microbot Medical®’S Liberty® Endovascular Robotic System Is Now Adopted By Multiple Accounts Across Key Territories Including Two Access-Pvi Pivotal Clinical Trial Sites
Brief: Microbot Medical Continues Its 2025 Momentum Announces Key 2026 Milestones